Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01309360
Other study ID # A 2009 24
Secondary ID
Status Completed
Phase Phase 4
First received March 4, 2011
Last updated July 6, 2011
Start date September 2009
Est. completion date April 2010

Study information

Verified date June 2011
Source Helios Research Center
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

Clinical aim: Does reducing the dose of local anesthetic in ultrasound-guided axillary plexus anesthesia have any effect on the success rate and additional parameters of block quality? Methodology: In this prospective cohort study three groups of 40 outpatients each were administered dosages of 1% prilocaine of either 40mL, 30mL or 20mL for axillary plexus anesthesia. Met-Hb was measured prior to administration of the block and then hourly until the Met-Hb concentration fell. Parameters of block quality and any adverse effects were recorded. The level of significance was defined with α ≤ 0.05.


Description:

Background

With the availability of high resolution portable ultrasound equipment, the use of sonography in the field of anesthesia has become more widespread in recent years. The investigators would like to draw attention to a meta-analysis of prospective randomized studies by Abrahams et al. as being representative of the numerous publications available. Compared to nerve stimulation, ultrasound-guided nerve blocks have a higher success rate with significantly fewer vascular punctures and shorter procedure times. However, the administration of ultrasound-guided regional anesthesia necessitates considerable equipment acquisition and training expenses. Nevertheless, the suggested benefits resulting from savings in time and local anesthetic, increased patient satisfaction and avoidance of complications should be considered in addition to the results from Abrahams et al.

The aim of the present work was to investigate whether an ultrasound-guided block combined with a reduced dose of the local anesthetic prilocaine altered the success rate or other parameters of block quality. Any adverse effects and the methaemoglobin concentration were also recorded.

Methodology

After receiving ethics committee approval and after informing patients, ultrasound-guided axillary plexus anesthesia was carried out on 120 adult outpatients in ASA risk groups I-II. The surgical spectrum covered procedures on the distal forearm or the hand (carpal tunnel syndrome, ganglion extirpation, removal of material, etc.). Provision of information and inclusion in the study was done in the anesthesia outpatients' clinic as part of the standard preoperative preparation. Prior to administering the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg). Application of the local anesthesia was done prospectively and single blind in 3 cohorts with decreasing dosage. The patients received either 400mg (group A), 300mg (group B) or 200mg (group C) of prilocaine 1%. The block was performed under sterile conditions using a portable ultrasound device (Sonosite S-Nerve) and a 24 G short bevel cannula with flexible tubing. The block was performed using combined out-of-plane (n. musculocutaneous) and in-plane techniques (n.radialis, n.medianus, n.ulnaris), usually from a single puncture site. The outpatients were cared for in the anesthesia care unit preoperatively and postoperatively until their discharge. NIBP, pulse oxymetry and ECG were continuously monitored. The discharge criteria were widespread regression of the block with a subjective feeling of well-being including adequate analgesia and stable vital signs with methemoglobin (Met-Hb) concentrations ≤ 5%. Met-Hb levels were measured using spectrophotometry prior to the anesthesia (baseline value) and then hourly after performing the block until a clear decrease became apparent. A complete sensory block of all 4 nerves within 60 minutes of administration of the local anesthetic was rated as a successful block.

For the statistical analysis the investigators selected distribution-free, nonparametric test methods. The Mann-Whitney U test was used when comparing 2 groups and the Kruskal-Wallis test or Fisher's exact test was used when comparing more than 2 groups. The level of significance was defined with α ≤ 0.05. With multiple paired comparisons the significance level was adjusted using the Bonferroni correction. The Bravais-Pearson correlation coefficient rho describes the relationship between the maximum Met-Hb value and the weight-based prilocaine dose in mg/kg.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date April 2010
Est. primary completion date April 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- elective surgery on the distal forearm or the hand

- adult outpatients, age 18-75 years old

- ASA-risk groups I-II (American Society of Anesthesiologists)

- Body Mass Index 17-35

- informed consent

Exclusion Criteria:

- severe coagulopathy

- local or systemic inflammatory response

- ASA-risk groups = Grad III

- severe anemia

- heart failure

- manifest shock

- other drugs with influence on methaemoglobinemia (nitrates, sulfonamides etc.)

- domestic care after surgery not ensured

- drug allergy : local anesthetics

- severe polyneuropathy

- pregnancy, lactation period

- participation in other studies

- non-cooperative patients

- addiction to drugs or alcohol

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
midazolam
Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
prilocaine 1%
40 outpatients : 40ml prilocaine 1% were administered for axillary plexus block
prilocaine 1%
40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
prilocaine 1%
40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Helios Research Center

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Complete Sensory Block The number of outpatients with complete sensory block of all 4 nerves (n.musculocutaneous, n.radialis, n.ulnaris,n.medianus) was registrated in each group. 60 minutes after administration of the local anesthetic No
Primary Number of Participants With Complete Motor Blocks To examine the extent of the motor block the manual muscle function test after Vladimir Janda was used. As a complete motor block was defined, when no motion (grade zero after Janda) of muscles innervated by the four blocked nerves (musculocutaneous, median, radial and ulnar nerve) was observed within 60 minutes after administration of the local anesthetic. Within 60 minutes after administration of the local anesthetic No
Primary Onset Time. Time from beginning of administration of the local anesthetic until complete sensoric block. within 60 minutes after administration of the local anesthetic No
Secondary Maximum Concentrations of Methemoglobin Concentration of Methemoglobin (Met-Hb) was measured using spectrophotometry prior to the anesthesia (baseline value) and then hourly after performing the block until a clear decrease became apparent. The maximum amount was reached in every case two or three hours after administration of the local anesthetic. 0,1,2,3,4 hours post-dose Yes
Secondary Number of Participants With Objective Adverse Events as a Measure of Safety and Tolerability In groups A, B and C was determined the rate of objective clinical signs of increased Met-Hb-levels : drops in oxygen saturation <93% using pulseoximetry or lip cyanosis. Outpatients were followed for the duration of hospital stay, an average of six hours. Yes
Secondary Number of Participants With Subjective Adverse Events as a Measure of Safety and Tolerability. In groups A, B and C was determined the rate of subjective clinical signs of increased Met-Hb-Levels : headaches or dizziness, when correlated with the peak-Met-Hb-Level. Outpatients were followed for the duration of hospital stay, an average of six hours. Yes
See also
  Status Clinical Trial Phase
Completed NCT02429414 - Video Double-Lumen Tube Prospective Randomized Study Phase 3
Completed NCT02516566 - Effects of PEEP on Optic Nerve Sheath Diameter During Robot-Assisted Laparoscopic Prostatectomy N/A
Completed NCT02248688 - Gastric Artery Embolization Trial for Lessening Appetite Nonsurgically N/A
Completed NCT01433029 - Objective Assessment of Technical Skills in Cardiothoracic Surgery N/A
Completed NCT02494856 - Comparison of the Clinical Efficacy of Naproxen, Associated or Not With Esomeprazol, in Lower Third Molar Removal Phase 4
Completed NCT02263443 - Appropriated Bowel Preparation Before Exploratory Laparotomy in Gynecologic Surgery N/A
Completed NCT02450487 - Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery Phase 4
Completed NCT01726231 - Evaluation of Abdominal Wall Lifting During Laparoscopic Direct Trocar Insertion N/A
Completed NCT01643616 - Ultrasound Guided Distal Sciatic Nerve Block - a Comparison With Nerve Stimulator Technique N/A
Completed NCT02906969 - Colonoscopy Educational Video Upon Inner City Population N/A
Completed NCT01580176 - Continuous GlucoseMonitor for Measurement of Blood Glucose Level N/A
Completed NCT02730026 - Comparison of the Clinical Efficacy of Ketoprofen, Associated or Not With Omeprazole in Lower Third Molar Removal Phase 4
Active, not recruiting NCT02525406 - Models for Improving Operating Room Productivity: Delays, Cancellations and Pre-admission Testing
Recruiting NCT01491165 - Safety and Efficacy of Stem Cell Transplantation for Treatment of Liver Cirrhosis Phase 2/Phase 3
Active, not recruiting NCT03169127 - Clinical Pharmacogenetic of Ibuprofen After Lower Third Molar Surgeries Phase 4